All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Not reported | 2013-003972-11 | Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer Randomisierte multizentrische Phase II/III Studie mit adju... | 2020-05-13 | due-trials |
| Reported results | 2014-000246-30 | Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (CRC) and iron deficiency anemia: a randomized multicenter treatment optimization study. I... | 2020-05-08 | due-trials |
| Reported results | 2014-002695-86 | PETRARCA / FLOT6 FLOT vs. FLOT/Herceptin/Perjeta for perioperative therapy of adenocarcinoma of the stomach and gastroesophageal junction expressing HER-2 A phase II/III trial of the AIO PETRARCA ... | 2020-07-17 | due-trials |
| Reported results | 2015-003118-26 | Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma RAMSES - a phase II/III trial of the AIO and GOIM RAMucirumab perioperatorio in co... | 2022-06-20 | due-trials |
| Ongoing | 2015-005171-24 | Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one pr... | not-yet-due | |
| Reported results | 2016-003850-33 | RAMOS A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to com... | 2022-11-25 | due-trials |
| Ongoing | 2017-000329-11 | Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer | not-yet-due | |
| Ongoing | 2017-001979-23 | A randomized, open-label Phase II/III efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric j... | not-yet-due | |
| Ongoing | 2017-002080-18 | Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs. FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – A... | not-yet-due | |
| Ongoing | 2017-003832-35 | Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial ... | not-yet-due | |
| Ongoing | 2017-004162-99 | RAMTAS A Phase III study of RAMucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients RAMTAS Ramucirumab in Kombination mit TAS... | not-yet-due | |
| Reported results Terminated | 2018-001124-20 | Efficacy of Olaratumab and Rechallenge with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients. An exploratory phase-II study - The OlaReDo Phase II Trial | 2020-06-25 | due-trials |
| Ongoing | 2018-001381-42 | IMMULAB – A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) | not-yet-due | |
| Not reported | 2018-001480-23 | IMMUNIB - An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) | 2022-10-27 | due-trials |
| Other | 2018-004778-81 | A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC... | not-yet-due | |
| Ongoing | 2019-001828-36 | Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping | not-yet-due | |
| Ongoing | 2019-002192-33 | Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy | not-yet-due | |
| Ongoing | 2019-002466-13 | Nivolumab with chemotherapy in pleural mesothelioma after surgery | not-yet-due | |
| Ongoing | 2019-003916-29 | - TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease: a randomized, open-label, multicenter phase II study | not-yet-due | |
| Ongoing | 2019-004597-26 | A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC - IMMUWIN | not-yet-due | |
| Ongoing | 2019-004728-39 | A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment Eine nicht randomisierte, einarmige, ... | not-yet-due | |
| Ongoing | 2020-000775-20 | A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function Eine Phase II Studie, in der ... | not-yet-due | |
| Reported results | 2020-001075-32 | RE-ExPEL A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on... | 2023-01-20 | due-trials |
| Ongoing | 2020-004210-35 | The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma... | not-yet-due | |
| Ongoing | 2020-004938-38 | ADVANCE: A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements ADVANCE: Eine einarmig... | not-yet-due | |
| Ongoing | 2021-000150-26 | Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – POL... | not-yet-due | |
| Ongoing | 2021-000355-40 | SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy S... | not-yet-due | |
| Ongoing | 2021-002389-41 | A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer | not-yet-due | |
| Ongoing | 2021-006512-87 | Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT – ... | not-yet-due | |
| Ongoing | 2022-001752-42 | The PRESTO Trial- Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indicat... | not-yet-due | |
| Ongoing | 2022-003398-51 | A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in pr... | not-yet-due |